Buscar
Mostrando ítems 21-30 de 469
Hipertensión arterial refractaria y uso de drogas anticonvulsivantes: Caso clínico
(Sociedad Médica de Santiago, 2001)
Different profiles of circulating arginase 2 in subtypes of preeclampsia pregnant women
(Elsevier B.V., 2021-06-01)
Background and aims: Preeclampsia (PE) is a gestational hypertensive disease responsible for high maternal and fetal morbidity and mortality. The increase in blood pressure is associated with a decrease in the bioavailability ...
Assessment of adherence to antihypertensive therapy Prevalencia y determinantes de adherencia a terapia antihipertensiva en pacientes de la Región Metropolitan
(Sociedad Medica de Santiago, 2015)
© 2015 Sociedad Medica de Santiago. All Rights Reserved.Background: Lack of adherence with medications is the main cause of antihypertensive treatment failure. Aim: To assess adherence to antihypertensive drugs and its ...
eNOS haplotypes affect the responsiveness to antihypertensive therapy in preeclampsia but not in gestational hypertension
(NATURE PUBLISHING GROUP, 2010)
Variations of the endothelial nitric oxide synthase (eNOS) gene have been associated with hypertensive disorders of pregnancy. We examined whether eNOS polymorphisms affect the therapeutic responses of women with gestational ...
An economic evaluation of antihypertensive therapies based on clinical trials
(HOSPITAL CLINICAS, UNIV SAO PAULOSAO PAULO, 2012)
OBJECTIVE: Hypertension is a major issue in public health, and the financial costs associated with hypertension continue to increase. Cost-effectiveness studies focusing on antihypertensive drug combinations, however, have ...
Matrix metalloproteinase-9 polymorphisms affect plasma MMP-9 levels and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy
(Nature Publishing GroupLondon, 2012)
Innovative Approaches to Hypertension Control in Low- and Middle-Income Countries
(Elsevier, 2017)
Elevated blood pressure, a major risk factor for ischemic heart disease, heart failure, and stroke, is the leading global risk for mortality. Treatment and control rates are very low in low- and middle-income countries. ...